[Pre-print, not peer reviewed]<\/i> The efficacy the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca; AZD1222) against the B.1.1.7 variant of SARS-CoV-2 was similar to the efficacy against parent lineages, with 74% efficacy (95% CI, 42-89%) against B.1.1.7 compared to 84% efficacy (95% CI, 71-91%) against non- B.1.1.7 lineages. Vaccine-induced antibodies had an approximately nine-fold reduction in neutralization activity against the B.1.1.7 variant compared to a canonical non-B.1.1.7 lineage in a live-virus neutralization assay.<\/p>\n
All participants received weekly nasal swabs for surveillance. Among those vaccinated with ChAdOx1 who subsequently became infected with SARS-CoV-2, both the duration of shedding and viral load was lower than among control participants. The authors suggest that this may result in a lower potential for transmission with vaccination.\u00a0<\/span><\/p>\n Emary et al. (Feb 4, 2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC. Pre-print downloaded Feb 5 <\/i>https:\/\/ssrn.com\/abstract=3779160<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" [Pre-print, not peer reviewed] The efficacy the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca; AZD1222) against the B.1.1.7 variant of SARS-CoV-2 was similar to the efficacy against parent lineages, with 74% efficacy (95% CI, 42-89%) against B.1.1.7 compared to 84% efficacy (95% CI, 71-91%) against non- B.1.1.7 lineages. Vaccine-induced antibodies had an approximately nine-fold reduction in neutralization activity…<\/p>\n